Works about RIBAVIRIN

Results: 3350
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.

    Published in:
    Liver International, 2017, v. 37, n. 9, p. 1314, doi. 10.1111/liv.13383
    By:
    • Hézode, Christophe;
    • Lebray, Pascal;
    • De Ledinghen, Victor;
    • Zoulim, Fabien;
    • Di Martino, Vincent;
    • Boyer, Nathalie;
    • Larrey, Dominique;
    • Botta ‐ Fridlund, Danielle;
    • Silvain, Christine;
    • Fontaine, Hélène;
    • D'Alteroche, Louis;
    • Leroy, Vincent;
    • Bourliere, Marc;
    • Hubert ‐ Fouchard, Isabelle;
    • Guyader, Dominique;
    • Rosa, Isabelle;
    • Nguyen ‐ Khac, Eric;
    • Fedchuk, Larysa;
    • Akremi, Raoudha;
    • Bennai, Yacia
    Publication type:
    Article
    11
    12

    Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.

    Published in:
    Liver International, 2017, v. 37, n. 5, p. 678, doi. 10.1111/liv.13322
    By:
    • Donato, Maria Francesca;
    • Morelli, Cristina;
    • Romagnoli, Renato;
    • Invernizzi, Federica;
    • Mazzarelli, Chiara;
    • Iemmolo, Rosa Maria;
    • Montalbano, Marzia;
    • Lenci, Ilaria;
    • Bhoori, Sherrie;
    • Pieri, Giulia;
    • Berardi, Sonia;
    • Caraceni, Paolo;
    • Martini, Silvia;
    • Angeli, Paolo;
    • Belli, Luca Saverio;
    • Bernabucci, Veronica;
    • Malinverno, Federica;
    • Monico, Sara;
    • Ottobrelli, Antonio;
    • Romano, Antonietta
    Publication type:
    Article
    13

    Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.

    Published in:
    Liver International, 2017, v. 37, n. 5, p. 653, doi. 10.1111/liv.13288
    By:
    • Pellicelli, Adriano M.;
    • Pace Palitti, Valeria;
    • Vignally, Pascal;
    • Ceccherini ‐ Silberstein, Francesca;
    • Siciliano, Massimo;
    • Giannelli, Valerio;
    • Moretti, Alessandra;
    • Tarquini, Pierluigi;
    • Scifo, Gaetano;
    • Messina, Vincenzo;
    • Ascione, Antonio;
    • Izzi, Antonio;
    • Marignani, Massimo;
    • D'Ambrosio, Cecilia;
    • Fondacaro, Lucia;
    • Ettorre, Giuseppe M.;
    • Ialongo, Pasquale;
    • Sacco, Rodolfo;
    • Perno, Carlo F.;
    • Barbarini, Giorgio
    Publication type:
    Article
    14
    15
    16
    17
    18

    A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.

    Published in:
    Liver International, 2016, v. 36, n. 8, p. 1101, doi. 10.1111/liv.13082
    By:
    • Kao, Jia ‐ Horng;
    • Chien, Rong ‐ Nan;
    • Chang, Ting ‐ Tsung;
    • Peng, Cheng ‐ Yuan;
    • Hu, Tsung ‐ Hui;
    • Lo, Gin ‐ Ho;
    • Wang, Horng ‐ Yuan;
    • Chen, Jyh ‐ Jou;
    • Yang, Jenny C.;
    • Knox, Steven J.;
    • Han, Lingling;
    • Mo, Hongmei;
    • Mathias, Anita;
    • Brainard, Diana M.;
    • Sheen, I ‐ Shyan;
    • Hsu, Yu ‐ Chun;
    • Chu, Chi ‐ Jen;
    • Chuang, Wan ‐ Long
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25

    Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.

    Published in:
    Liver International, 2016, v. 36, n. 2, p. 189, doi. 10.1111/liv.12964
    By:
    • Everson, Gregory T.;
    • Sims, Karen D.;
    • Thuluvath, Paul J.;
    • Lawitz, Eric;
    • Hassanein, Tarek;
    • Rodriguez ‐ Torres, Maribel;
    • Desta, Tadesse;
    • Hawkins, Trevor;
    • Levin, James M.;
    • Hinestrosa, Federico;
    • Rustgi, Vinod;
    • Schwartz, Howard;
    • Younossi, Zobair;
    • Webster, Lynn;
    • Gitlin, Norman;
    • Eley, Timothy;
    • Huang, Shu ‐ Pang;
    • McPhee, Fiona;
    • Grasela, Dennis M.;
    • Gardiner, David F.
    Publication type:
    Article
    26
    27
    28
    29
    30
    31
    32

    Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.

    Published in:
    Liver International, 2015, v. 35, n. 7, p. 1833, doi. 10.1111/liv.12759
    By:
    • Sultanik, Philippe;
    • Mallet, Vincent;
    • Lagaye, Sylvie;
    • Casrouge, Armanda;
    • Dorival, Céline;
    • Barthe, Yoann;
    • Fontaine, Hélène;
    • Hézode, Christophe;
    • Mottez, Estelle;
    • Bronowicki, Jean ‐ Pierre;
    • Carrat, Fabrice;
    • Theodorou, Ioannis;
    • Abel, Laurent;
    • Gayat, Etienne;
    • Fontanet, Arnaud;
    • Pol, Stanislas;
    • Albert, Matthew L.
    Publication type:
    Article
    33
    34
    35
    36
    37

    Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study.

    Published in:
    Liver International, 2015, v. 35, n. 2, p. 448, doi. 10.1111/liv.12703
    By:
    • Berg, Thomas;
    • Andreone, Pietro;
    • Pol, Stanislas;
    • Roberts, Stuart;
    • Younossi, Zobair;
    • Diago, Moises;
    • Lawitz, Eric J.;
    • Focaccia, Roberto;
    • Foster, Graham R.;
    • Horban, Andrzej;
    • Lonjon ‐ Domanec, Isabelle;
    • DeMasi, Ralph;
    • Picchio, Gaston;
    • Luo, Donghan;
    • De Meyer, Sandra;
    • Zeuzem, Stefan
    Publication type:
    Article
    38
    39

    Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM- SVR study.

    Published in:
    Liver International, 2015, v. 35, n. 1, p. 79, doi. 10.1111/liv.12588
    By:
    • Gane, Edward J.;
    • Pockros, Paul J.;
    • Zeuzem, Stefan;
    • Marcellin, Patrick;
    • Shikhman, Anna;
    • Bernaards, Coen;
    • Zhou, Julian;
    • Yetzer, Ellen S.;
    • Ballester, Rosa;
    • Dwyer, Cindy;
    • Tong, Xiao;
    • Nájera, Isabel;
    • Bertasso, Anne;
    • Hammond, Janet;
    • Kindrick, Amy;
    • Morcos, Peter N.;
    • Smith, Patrick;
    • Stancic, Saray;
    • Shulman, Nancy S.
    Publication type:
    Article
    40
    41
    42

    In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.

    Published in:
    Liver International, 2014, v. 34, n. 7, p. e217, doi. 10.1111/liv.12352
    By:
    • Mangia, Alessandra;
    • Bányai, Tivadar;
    • De Bartolomeo, Giuseppe;
    • Gervain, Judit;
    • Habersetzer, François;
    • Mulkay, Jean-Pierre;
    • Ouzan, Denis;
    • Parruti, Giustino;
    • Passariello, Nicola;
    • Remy, Andre-Jean;
    • Rizzetto, Mario;
    • Shiffman, Mitchell L.;
    • Tice, Alan D.;
    • Schmitz, Manuela;
    • Tatsch, Fernando;
    • Rodriguez-Torres, Maribel
    Publication type:
    Article
    43
    44
    45

    A Double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects

    Published in:
    Liver International, 2014, v. 34, n. 6, p. e89, doi. 10.1111/liv.12334
    By:
    • Gardner, Stephen;
    • Cutrell, Amy;
    • Elko ‐ Simms, Cindy;
    • Adkison, Kimberly;
    • Hamatake, Robert;
    • Walker, Jill;
    • Rodriguez ‐ Torres, Maribel;
    • Hong, Zhi
    Publication type:
    Article
    46

    Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.

    Published in:
    Liver International, 2014, v. 34, n. 5, p. 707, doi. 10.1111/liv.12300
    By:
    • Manns, Michael P.;
    • McCone, Jonathan;
    • Davis, Mitchell N.;
    • Rossaro, Lorenzo;
    • Schiff, Eugene;
    • Shiffman, Mitchel L.;
    • Bacon, Bruce;
    • Bourliere, Marc;
    • Sulkowski, Mark S.;
    • Bruno, Savino;
    • Balart, Luis;
    • Bronowicki, Jean‐Pierre;
    • Kwo, Paul;
    • Poordad, Fred;
    • Felizarta, Franco;
    • Reddy, K. Rajender;
    • Helmond, Frans A.;
    • Sings, Heather L.;
    • Pedicone, Lisa D.;
    • Burroughs, Margaret
    Publication type:
    Article
    47

    Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients.

    Published in:
    Liver International, 2014, v. 34, n. 4, p. 551, doi. 10.1111/liv.12279
    By:
    • Frei, Pascal;
    • Leucht, Anna ‐ Kathrin;
    • Held, Ulrike;
    • Kofmehl, Reto;
    • Manser, Christine N.;
    • Schmitt, Johannes;
    • Mertens, Joachim;
    • Rau, Monika;
    • Baur, Katharina;
    • Gerlach, Tilman;
    • Negro, Francesco;
    • Heim, Markus;
    • Moradpour, Darius;
    • Cerny, Andreas;
    • Dufour, Jean ‐ François;
    • Müllhaupt, Beat;
    • Geier, Andreas
    Publication type:
    Article
    48
    49
    50